Furthermore, BACE1 inhibitors exert dual beneficial effects on pathological progression in the brain at a preclinical AD stage by directly suppressing the Aβ pathway and by ameliorating insulin resistance through decreased BACE1 cleavage of cell-surface IR. The gene discussed is INS; the disease is Alzheimer disease.